Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

BioMarin Licenses Fabry Disease Therapy From GC Biopharma, Hanmi Pharm

By Public Technologies
  • BioMarin entered an exclusive license agreement with GC Biopharma and Hanmi Pharm for investigational Fabry disease therapy HM15421/GC1134A.
  • The deal grants worldwide rights excluding Korea, where GC and Hanmi retain commercialization rights.
  • Terms include $70 million upfront, up to $405 million in development and commercial milestones, and tiered royalties on net sales.
  • The long-acting, subcutaneous enzyme replacement therapy is in a Phase 1/2 trial.
  • Following that study, BioMarin will assume sole responsibility for subsequent clinical development, manufacturing and commercialization outside Korea.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610290845PR_NEWS_USPR_____SF84234) on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.